Active Clinical Trials

September 17, 2024
PrECOG logo
September 17, 2024
Categories

Now Enrolling: PrE1702 Real-World Data Study for Patients With EGFR-Mutated Non-Small Cell Lung Cancer Not Enrolled in Clinical Trials

This innovative real-world data study is developing an infrastructure to conduct a study comparing outcomes in patients with EGFR-mutated NSCLC receiving osimertinib with or without chemotherapy and not enrolled in a clinical trial
Do you like it?
0 Read more
July 3, 2024
July 3, 2024
Categories

Amended Trial: Nataliya Uboha Gives an Update on the EA2183 Trial for Patients With Esophageal and Gastric Adenocarcinoma

The changes broaden eligibility for patients and permit more therapeutic options once enrolled in this randomized phase 3 trial, which explores the addition of radiotherapy to the usual treatment (chemotherapy) in people with esophagus and stomach cancer with limited spread
Do you like it?
2 Read more
March 7, 2024
March 7, 2024
Categories

Now Enrolling: EA5221/ACHIEVE for Older Adults With Advanced Non-Small Cell Lung Cancer

ACHIEVE is the first randomized phase 3 study to focus on older adults with advanced non-small cell lung cancer who are treated with pembrolizumab alone compared to those treated with pembrolizumab plus chemotherapy
Do you like it?
0 Read more
March 7, 2024
Lung x-ray on iPad
March 7, 2024
Categories

Trial Spotlight: Helena Yu Gives an Update on the EA5182 Trial for EGFR-Mutant Non-Small Cell Lung Cancer

This phase 3 randomized controlled trial is comparing first-line treatment with osimertinib plus bevacizumab versus osimertinib alone in patients with metastatic, EGFR-mutant non-small cell lung cancer
Do you like it?
0 Read more
1234567891011